Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ): HQ2231 has been approved for clinical trials.

10/01/2025

GMT Eight

Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) announced that its wholly-owned subsidiary, Hangzhou Bio-Sincerity Pharma-Tech (Zhuhai Hengqin) Co., Ltd., has recently received the National Medical Products Administration (NMPA) approval notification for clinical trials. The company's independently developed drug, HQ2231, will undergo clinical trial research. The drug is indicated for schizophrenia.

On January 10th, KINGDEE INT'L (00268) spent 5.4962 million Hong Kong dollars to repurchase 700,000 shares.

TONGCHENGTRAVEL (00780)s subsidiary, HopeGoo, officially integrates with Octopus Card. Tourists in Hong Kong can now book high-speed train tickets to mainland China.

Contact: contact@gmteight.com

Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ): HQ2231 has been approved for clinical trials.

RECOMMEND

US Stock Market Move | The United States plans to tighten regulations on the export of AI chips, causing AMD Semiconductor (AMD.US) to fall nearly 5%.

US Stock Market Move | Lowering the 2025 fiscal year performance guidance, the constellation brand (STZ.US) plummeted more than 10%.

US Stock Market Move | Los Angeles fire causes widespread damage, insurance sector plunges.